SequelSEC

GeoVax Labs, Inc. GOVX

Pharmaceutical Preparations · CIK 0000832489 · Fiscal year ends 1231

Revenue
$2.49M
Fiscal year ended 2025-12-31
Operating income
-$21.64M
Fiscal year ended 2025-12-31
Free cash flow
-$21.50M
Fiscal year ended 2025-12-31

GeoVax Labs, Inc. (GOVX) reported revenue of $2.49M and net income of -$21.46M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from GeoVax Labs, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

GeoVax Labs, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$2.49M$3.95M$0$81.53K$385.50K$1.82M$1.18M$963.20K$1.08M$828.92K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$21.64M-$25.14M-$26.74M-$14.03M-$18.75M-$2.82M-$2.37M-$2.56M-$2.17M-$3.27M
Net income-$21.46M-$24.99M-$25.97M-$14.02M-$18.57M-$2.96M-$2.37M-$2.56M-$2.17M-$3.27M
Research & development$18.12M$23.71M$20.72M$9.12M$15.55M$2.44M$1.91M$1.88M$2.02M$1.97M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0UnavailableUnavailableUnavailable$0$0$0$0$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.01M$5.39M$6.02M$4.99M$3.58M$2.20M$1.64M$1.65M$1.23M$2.13M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

GeoVax Labs, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$3.09M$5.51M$6.45M$27.61M$11.42M$9.88M$283.34K$259.70K$312.73K$454.03K
Total assets$6.34M$8.16M$9.28M$31.35M$11.80M$10.39M$468.88K$642.06K$490.24K$610.22K
Current assets$5.31M$7.93M$7.89M$28.94M$11.63M$10.24M$447.26K$619.70K$448.07K$544.38K
Total liabilities$2.52M$3.11MUnavailable$4.75M$7.44M$825.05K$2.04M$1.66M$811.29KUnavailable
Current liabilities$1.94M$3.11M$3.52M$4.75M$5.44M$810.31K$2.02M$1.62M$811.29K$369.85K
Total equity incl. NCI$3.83M$5.05M$5.76M$26.60M$4.36M$9.57M-$1.57M-$1.02M-$321.06K$240.37K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$0$659.41K$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$790.75K$1.85M$2.80M$1.75M$2.06M$267.70K$152.65K$125.86K$77.58K$75.61K

Cash flow

GeoVax Labs, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$21.47M-$24.68M-$25.17M-$19.03M-$11.20M-$2.75M-$1.40M-$1.54M-$1.69M-$1.95M
Capital expenditures$27.61K$20.65K$48.95K$134.26K$47.72K$156.79K$7.61KUnavailable$4.35KUnavailable
Investing cash flow-$27.61K-$20.65K-$48.95K-$134.26K-$47.72K-$156.79K-$7.61KUnavailable-$4.35KUnavailable
Financing cash flow$19.08M$23.75M$4.06M$35.35M$12.78M$12.51M$1.43M$1.49M$1.55M$1.34M
Net change in cash-$2.42M-$945.65K-$21.16M$16.19M$1.54M$9.60M$23.64K-$53.03K-$141.30K-$606.32K
Stock-based compensation$1.12M$528.64K$1.07M$902.07K$369.99K$64.46K$327.50K$469.72K$57.22K$967.67K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$68.76K$95.37K$74.17K$56.28K$38.52K$19.66K$8.35K$19.80K$28.03K$28.78K

Derived

GeoVax Labs, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow-$21.50M-$24.70M-$25.22M-$19.16M-$11.24M-$2.91M-$1.41MUnavailable-$1.69MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-869.3%-635.8%Unavailable-17207.5%-4862.7%-154.5%-201.8%-266.1%-202.2%-394.9%
FCF margin-863.8%-624.5%Unavailable-23507.2%-2916.8%-159.4%-119.6%Unavailable-157.4%Unavailable
SBC / revenue44.8%13.4%Unavailable1106.5%96.0%3.5%27.9%48.8%5.3%116.7%
Current ratio2.74x2.55x2.24x6.10x2.14x12.63x0.22x0.38x0.55x1.47x
Revenue YoY growth-37.1%Unavailable-100.0%-78.9%-78.9%55.1%22.1%-10.4%29.7%Unavailable
Net margin-862.3%-632.0%Unavailable-17198.3%-4817.2%-162.2%-201.6%-265.8%-201.8%-394.7%
R&D / revenue728.0%599.6%Unavailable11190.9%4034.8%134.0%162.5%195.0%187.6%237.8%
CapEx / revenue1.1%0.5%Unavailable164.7%12.4%8.6%0.6%Unavailable0.4%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GOVX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-27View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-07-28View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.